Skip to main content
Figure 8 | Journal of Translational Medicine

Figure 8

From: Survivin-responsive conditionally replicating adenovirus kills rhabdomyosarcoma stem cells more efficiently than their progeny

Figure 8

In vivo therapeutic effects of Surv.m- CRA against tumors in mice. Tumor nodules were generated in mice by implantation of RSC-enriched rhabdomyosarcoma cells, and a single intratumoral injection of Surv.m-CRA, Ad.dE1.3, or PBS was subsequently administered to each nodule. (A) The macroscopic tumor size after each treatment. A significant difference was found between mice treated with Surv.m-CRA and those treated with either control (Ad.dE1.3 or PBS) (P < 0.05). (B) Representative macroscopic pictures of a tumor nodule 42 days after each treatment. (C) Representative histopathologic pictures of hematoxylin/eosin-stained sections in the tumor nodule 42 days after each treatment. In Ad.dE1.3-treated and the PBS-treated mice, tumor nodules mainly consisted of viable tumor cells exhibiting malignant features without large necrotic areas. By contrast, in Surv.m-CRA–treated mice, tumor nodules mainly consisted of large necrotic areas with loose connective tissues and without viable tumor cells. Original magnification: 40× (top; scale bar, 1 mm) and 400× (bottom; scale bar, 100 mm).

Back to article page